Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines. - Wikidata - awgldk - TriplyDB

Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines.

Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines.

http://www.wikidata.org/entity/Q40427675

about

Redox-directed cancer therapeutics: molecular mechanisms and opportunities Redox Homeostasis and Cellular Antioxidant Systems: Crucial Players in Cancer Growth and Therapy Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.Motexafin gadolinium in the treatment of brain metastases Dynamic network of transcription and pathway crosstalk to reveal molecular mechanism of MGd-treated human lung cancer cells Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase Correction of spatial bias in oligonucleotide array data.Texaphyrins and water-soluble zinc(II) ionophores: development, mechanism of anticancer activity, and synergistic effects mtDNA depletion confers specific gene expression profiles in human cells grown in culture and in xenograft.Profiling of zinc-altered gene expression in human prostate normal vs. cancer cells: a time course study.Synthesis and anticancer properties of water-soluble zinc ionophores.Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies Crown ether functionalized texaphyrin monomers and dimers.Synthesis and biologic properties of hydrophilic sapphyrins, a new class of tumor-selective inhibitors of gene expression Overcoming biochemical pharmacologic mechanisms of platinum resistance with a texaphyrin-platinum conjugate.Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a children's oncology group phase 2 study.Targeting Antioxidant Pathways with Ferrocenylated N-Heterocyclic Carbene Supported Gold(I) Complexes in A549 Lung Cancer Cells.Catalytic antioxidants to treat amyotropic lateral sclerosis.Motexafin gadolinium: a novel radiosensitizer for brain tumors.Motexafin gadolinium injection for the treatment of brain metastases in patients with non-small cell lung cancer.Lanthanides: Applications in Cancer Diagnosis and Therapy.Motexafin gadolinium: a promising radiation sensitizer in brain metastasis.Current State of Metal-Based Drugs for the Efficient Therapy of Lung Cancers and Lung Metastases.In Silico Prediction of Mechanism of Action for Cancer Therapeutics.New polyethyleneglycol-functionalized texaphyrins: synthesis and in vitro biological studies.Motexafin gadolinium: a novel radiosensitizer for brain tumors.Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of ≤ 6 brain metastases: a multi-institutional phase II trial.

P2860

Q24645584-3F49B0D9-01AA-4D62-A149-799B6788BB30 Q26740191-D0725E6A-EE7F-4230-9B5F-1AA15580F2FC Q27310843-DE0FCEB3-EC08-41E4-86AE-F17BE0A0558C Q28285963-23A505DE-3CD0-4C7C-9729-DBEFA7AB0F23 Q28484052-5A6609A5-3CB0-44BB-B29A-BF6A1B17945A Q28567883-42EB9143-C496-4EF5-89B0-F1FCCAE4AD13 Q30614370-96202DE0-0A22-4101-9E1F-87CE5854834D Q30858160-ADC7029A-5142-49F5-B394-E832340841C4 Q33382286-2C1ED9E5-4228-4FA6-9FCB-9C0F054B972C Q33649966-4CF463CE-F655-4F54-AA5A-6D7D62D79181 Q34551766-7AD0D960-9914-4CCA-8E64-995187A3F7E1 Q34570658-C0488D13-8F14-47C6-A366-3514FFC2B343 Q35401147-A7A49D2E-1920-4024-9204-BF29924FA8FA Q35614104-7BD46B70-0AA2-44D5-8D2E-8C082E72CFA1 Q36294083-CBFCE68B-37D0-49B5-8EC3-3D0E972D6D62 Q36485991-174C720C-EFF9-4F7A-8DDA-8D50B9AC5FF9 Q36604338-31989AAA-C02B-4F58-8730-CF3FE149816A Q36623068-53838426-F8CB-44DF-8CA2-F68F127883D5 Q36842747-45111771-EC56-4828-A90C-CC5D5B10D000 Q36920440-017299E0-9487-4C04-A708-AD90DD28F527 Q37095640-6160570F-1385-49B1-A0C2-B2F23E24D4FA Q38014582-2F9AD3DD-5754-4400-9A76-D70A2995183E Q38669290-26E693B6-6C22-417D-BD97-5C367EDA1483 Q39375647-42CD7982-277F-4491-B98C-61951E483535 Q40293545-0C4C9B53-78A6-43F6-A44A-99E4E9869CF4 Q48500564-D25360B9-3490-477E-A09B-2D8403C95978 Q53154556-B6A3EB37-3595-4BA7-9F9B-B2A74942D238

P2860

Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines.

http://www.wikidata.org/entity/Q40427675

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines.

@en

type

label

Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines.

@en

prefLabel

Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines.

@en

P1433

Q40427675-C29DA9CB-138D-41FE-BDB4-6AB0445DA305

P1476

Q40427675-7E7C8107-46D7-46AD-9A90-34AB39066068

P2093

Q40427675-0BFF9ED9-D7EE-4336-84E9-0BDCF4F3C6DD

Q40427675-12C824FE-5C7B-44B3-A3C4-91EAE8720AEE

Q40427675-19601586-B044-43FB-A6E0-957EA8735B9F

Q40427675-282686E0-0A33-4C38-89B3-11781C2EF40C

Q40427675-79793301-D4C9-4B61-87E9-D5461AE5A5AE

Q40427675-92B3F53B-0558-405F-B182-D1C526748F70

Q40427675-9608EE46-1AE7-490C-B19E-2CE7E2B7004D

Q40427675-9E7D9E7C-3868-46A2-84D0-8400C4C496A7

Q40427675-A8D2EB3F-4491-4E44-A2B8-C754F3821DC6

Q40427675-AF421FE0-DEC6-466C-9CBA-FF1A05BBD462

P304

Q40427675-64572F7C-58F4-49AD-9E4A-2A5A13547EE8

P31

Q40427675-AA7FEEA9-052B-4EAA-B838-34A898FC9D77

P356

Q40427675-1875BF4D-E2F2-4ED8-B81C-4696D4A311F2

P407

Q40427675-DA12CCA2-81CA-4625-B47E-85E40C9579E7

P433

Q40427675-FD94E5CD-F6CF-41C1-A03F-AF2AB352E6D8

P478

Q40427675-C81B9EC1-7637-4F8D-B359-B817C69B6C25

P577

Q40427675-97D73571-DFE1-42F3-AB6B-34F750B899F6

P5875

Q40427675-C1F84FB3-83E5-4584-8D31-65063B33A48C

P698

Q40427675-DF0A71C8-4AB6-4872-81F9-C2BFC8CA437D

P356

0008-5472.CAN-04-4099

P1433

Cancer Research

P1476

Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines.

@en

P2093

Cheryl Lepp

http://www.w3.org/2001/XMLSchema#string

Dale Miles

http://www.w3.org/2001/XMLSchema#string

Danny Chawannakul

http://www.w3.org/2001/XMLSchema#string

Darren Magda

http://www.w3.org/2001/XMLSchema#string

John E Biaglow

http://www.w3.org/2001/XMLSchema#string

Joseph G Hacia

http://www.w3.org/2001/XMLSchema#string

Mazen W Karaman

http://www.w3.org/2001/XMLSchema#string

Mimi Mesfin

http://www.w3.org/2001/XMLSchema#string

Philip Lecane

http://www.w3.org/2001/XMLSchema#string

Richard A Miller

http://www.w3.org/2001/XMLSchema#string

P304

3837-3845

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-04-4099

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P577

2005-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7871687

http://www.w3.org/2001/XMLSchema#string

P698

15867382

http://www.w3.org/2001/XMLSchema#string